Kazia Therapeutics (KZIA) Common Equity (2009 - 2025)
Kazia Therapeutics' (KZIA) quarterly Common Equity came in at $30.5 million in Q4 2025, up 1325.28% YoY from $2.1 million in Q4 2024, and up 673.85% on a QoQ basis from -$5.3 million in Q2 2025.
Kazia Therapeutics (KZIA) Common Equity (2009 - 2025) Analysis & Trends
Kazia Therapeutics (KZIA) has 17 years of Common Equity data on file, last reported at $30.5 million in Q4 2025.
- Quarterly Common Equity rose 1325.28% year-over-year to $30.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $30.5 million (up 1325.28% YoY) and the FY2025 annual result came in at -$5.3 million, up 19.47% from the prior year.
- Common Equity improved to $30.5 million in Q4 2025, from -$5.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $30.5 million in Q4 2025 to a low of -$6.6 million in Q2 2024.
- A 5-year average of $9.6 million and a median of $7.8 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity slumped 181.97% — and 2025, when it surged 1325.28%.
- Tracing KZIA's Common Equity over 5 years: stood at $18.4 million in 2021, then tumbled by 58.73% to $7.6 million in 2022, then slumped by 54.94% to $3.4 million in 2023, then tumbled by 172.61% to -$2.5 million in 2024, then surged by 1325.28% to $30.5 million in 2025.
- The last three Common Equity figures came in at $30.5 million (Q4 2025), -$5.3 million (Q2 2025), and -$2.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Kazia Therapeutics | 4.22 Bn | 4.22 Bn | - | 30.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 30.51 Mn |
| Jun 30, 2025 | -5.32 Mn |
| Dec 31, 2024 | -2.49 Mn |
| Jun 30, 2024 | -6.60 Mn |
| Dec 31, 2023 | 3.43 Mn |
| Jun 30, 2023 | 8.05 Mn |
| Dec 31, 2022 | 7.61 Mn |
| Jun 30, 2022 | 13.09 Mn |
| Dec 31, 2021 | 18.44 Mn |
| Jun 30, 2021 | 29.15 Mn |
| Dec 31, 2020 | 23.15 Mn |
| Jun 30, 2020 | 9.26 Mn |
| Dec 31, 2019 | 8.37 Mn |
| Jun 30, 2019 | 9.94 Mn |
| Dec 31, 2018 | 13.18 Mn |
| Jun 30, 2018 | 14.57 Mn |
| Jun 30, 2017 | 19.03 Mn |
| Dec 31, 2016 | 19.33 Mn |
| Jun 30, 2016 | 18.92 Mn |
| Dec 31, 2015 | 32.14 Mn |